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Abstract
 
The frequencies of the newly identified streptococcal superantigen genes 
 
smez
 
, 
 
spe-g
 
, and 
 
spe-h
 
were determined in a panel of 103 clinical isolates collected between 1976 and 1998 at various
locations throughout New Zealand. 
 
smez
 
 and 
 
spe-g
 
 were found in every group A 
 
Streptococcus
 
(GAS) isolate, suggesting a chromosomal location. The 
 
spe-h
 
 gene was found in only 24% of
the GAS isolates and is probably located on a mobile DNA element. The 
 
smez
 
 gene displays
extensive allelic variation and appears to be in linkage equilibrium with the M/emm type. 22
novel 
 
smez
 
 alleles were identified from 21 different M/emm types in addition to the already re-
ported alleles 
 
smez
 
 and 
 
smez-2
 
 with sequence identities between 94.5 and 99.9%. Three alleles
are nonfunctional due to a single base pair deletion. The remaining 21 alleles encode distinct
SMEZ variants. The mosaic structure of the 
 
smez
 
 gene suggests that this polymorphism has
arisen from homologous recombination events rather than random point mutation. The re-
cently resolved SMEZ-2 crystal structure shows that the polymorphic residues are mainly sur-
face exposed and scattered over the entire protein. The allelic variation did not affect either V
 
b
 
specificity or potency, but did result in significant antigenic differences. Neutralizing antibody
responses of individual human sera against different SMEZ variants varied significantly. 98% of
sera completely neutralized SMEZ-1, but only 85% neutralized SMEZ-2, a very potent variant
that has not yet been found in any New Zealand isolate. SMEZ-specific V
 
b
 
8 activity was
found in culture supernatants of 66% of the GAS isolates, indicating a potential base for the de-
velopment of a SMEZ targeting vaccine.
Key words: superantigen • streptococcal exotoxin • multiple allelic variation • gene mosaic • 
antigen variation
 
Introduction
 
Since the 1980s, there has been an alarming increase in
group A 
 
Streptococcus
 
 (GAS)
 
1
 
-mediated severe invasive dis-
ease (SID) around the world (1–5). Streptococcal invasive
disease may include soft tissue infections, such as cellulitis,
and necrotizing fasciitis or deeper infections, such as septic
scarlet fever (SF) and bacteremia (6). The most severe form
of invasive infection results in clinical symptoms similar to
those seen in patients with toxic shock syndrome (TSS)
caused by 
 
Staphylococcus aureus
 
 and was therefore described
as streptococcal toxic shock–like syndrome (STLS) (7, 8).
Characteristic symptoms of STLS include hypotension or
shock, fever, rash, renal impairment, vomiting, and diar-
rhea (9). The multiorgan involvement in STLS suggests
that a toxin produced by 
 
Streptococcus pyogenes
 
 might be in-
volved in pathogenesis. Prime candidates are the strepto-
coccal pyrogenic exotoxins (SPEs), a family of highly mi-
togenic proteins secreted individually or in certain
combinations by many 
 
S
 
.
 
 pyogenes
 
 strains. Together with
the staphylococcal enterotoxins (SEs) and the toxic shock
syndrome toxin (TSST), they belong to a large family of
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Abbreviations used in this paper:
 
 ET, electrophoresis type; GAS, group A
 
Streptococcus
 
; GST, glutathione 
 
S
 
-transferase; KD, Kawasaki disease;
MNT, M-nontypable; SAg, superantigen; SE, staphylococcal entero-
toxin; SF, scarlet fever; SID, severe invasive disease; SMEZ, streptococcal
mitogenic exotoxin; SPE, streptococcal pyrogenic exotoxin; STLS, strep-
tococcal toxic shock-like syndrome; TSS, toxic shock syndrome. 
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proteins, also known as bacterial superantigens (SAgs), with
similar amino acid sequence, protein structure, and func-
tional activities (10, 11). SAgs simultaneously bind to
MHC class II antigens and TCR molecules and thereby
stimulate a large number of T cells in a TCR V
 
b
 
–specific
mode. This event leads to the release of high systemic levels
of cytokines, such as TNF-
 
a
 
 and IL-1
 
b
 
, and of T cell me-
diators like IL-2 and IFN-
 
g
 
 (12–14).
It has also been suggested that bacterial SAgs are impli-
cated in other diseases, such as acute rheumatic fever and
Kawasaki disease (KD) (6, 15, 16). SPE-A has long been as-
sociated with the ability of GAS to cause SF and STLS, and
is believed to be the primary cause of the skin rash in SF (8,
17, 18). Although it has been shown that SPEs can cause
pathological conditions including fever and shock (19) and
that severe streptococcal infections are associated with cer-
tain exotoxin-producing strains (17, 20, 21), a correlation
between disease and a particular exotoxin and/or 
 
S
 
.
 
 py-
ogenes
 
 strain remains elusive. Yu and Ferretti performed
molecular epidemiologic analysis on 300 general 
 
S
 
.
 
 pyogenes
 
clinical isolates (from patients with a variety of diseases, ex-
cept SF) and found the 
 
speA
 
 gene with a frequency of only
15% (21). Among 146 isolates from patients with SF, 45%
were shown to contain 
 
speA
 
. Hauser et al. analyzed 34 
 
S
 
.
 
pyogenes
 
 isolates from patients with STLS and found the
 
speA
 
 gene in 85%. The 
 
speC
 
 gene was found in only 21%
of the isolates (20). Several investigators reported a correla-
tion between STLS and serotypes M1, M3, T3, and M12
and that 
 
speA
 
 was mostly, but not exclusively, found in
M1- and M3-type strains from patients with SF (17, 20,
21). On the other hand, a genetic and phenotypic diversity
among 
 
S
 
.
 
 pyogenes
 
 isolates from severe invasive infections
and STLS was reported in the United States (22), and Forni
et al. found an M-nontypable (MNT) strain to be common
in STLS patients (9). Furthermore, Hsueh and co-workers
found no association of severe invasive disease in Taiwan
with any SPE (23).
Four allelic variants of the 
 
speA
 
 gene have been found in
 
S. pyogenes
 
 so far (24). The 
 
speA1
 
 allele occurs in many dis-
tinct clonal lines, but expression of SPE-A2 and SPE-A3,
which are characterized by single amino acid substitutions,
was shown in two single clones that have caused the major-
ity of STLS episodes in the last decade (24, 25). Musser et
al. reported that all contemporary strains assigned to elec-
trophoresis types (ETs) 1 and 2 (two highly pathogenic
clones, which generally express serotype M1 and M3, re-
spectively) have the 
 
speA2
 
 and 
 
speA3
 
 allelic variants, re-
spectively (25). In contrast, ET1 and 2 isolates from disease
episodes in the 1920s and 1930s contain the 
 
speA1
 
 allele,
suggesting temporal variation. Kline and Collins showed
that SPE-A3 has a significantly increased mitogenic activity
and MHC class II affinity compared with SPE-A1 and
SPE-A2 (26). These results suggest that SPE-A3 represents
a more active form of SPE-A and might explain the fluctu-
ation in severity and disease frequency of severe invasive
infections.
The implication of other exotoxins, like SPE-C and
SSA, in streptococcal infections is even less clear and is as-
 
sumed on the basis that not all cultures from patients with
STLS or other severe invasive diseases express SPE-A.
Since some cases of SID cannot be correlated to any of
the known SPEs, there is a suggestion that one or more
novel SPEs might play a role in the resurgence of SID in
recent years. Recently, we reported the identification of
the streptococcal exotoxins SMEZ-2, SPE-G, SPE-H, and
SPE-J (27). SMEZ-2 is an allelic variant of the previously
described SMEZ (28). Functional analysis using recombi-
nant protein revealed that SPE-G and SPE-H target human
T cells carrying the V
 
b
 
2 region, a specificity they share
with SPE-C and TSST. SMEZ and SMEZ-2 target human
V
 
b
 
4 and V
 
b
 
8 T cells, a unique specificity among strepto-
coccal SAgs. A selective expansion of V
 
b
 
2 and V
 
b
 
8 T cells
has been reported in patients with KD (15), but the poten-
tial role of SAgs in triggering this disease remains unclear.
In this report, we present evidence for wide genotypic
variation in SMEZ among a panel of 103 clinical isolates
selected to provide a spectrum of distinct M/emm types
occurring in the community and to provide representation
of subtypes within specific M types. Thus far, 24 
 
smez
 
 al-
leles have been identified in 22 different M/emm types.
Moreover, the frequency of 
 
smez
 
 in 95 analyzed GAS iso-
lates approached 100%, making it the most common of all
known 
 
sag
 
 genes, at least within New Zealand. Given the
fact that SMEZ is also the most potent SAg produced by 
 
S
 
.
 
pyogenes
 
, this has significant implications for its involvement
in 
 
Streptococcus
 
-mediated disease.
 
Materials and Methods
 
Bacterial Isolates.
 
The 103 streptococcal isolates were obtained
from the Institute of Environmental Science and Research in
Porirua, New Zealand. Group 1 consists of 52 isolates (including
5 
 
b
 
-hemolytic non-GAS strains) that were taken from various
parts of New Zealand between 1976 and 1996. Group 2 contains
51 isolates (including 4 non-GAS) collected from South Auck-
land schools in 1998. The non-GAS were 
 
Streptococcus agalactiae
 
(group B), 
 
Streptococcus equis
 
 (group C), and 
 
Streptococcus
 
 
 
spp.
 
(group G). Genotyping of all isolates was undertaken blinded to
their strain definition. Two duplicates were included to ensure
accuracy of the testing. The results of the duplicate isolates were
not included in the overall statistics.
 
Genomic DNA Preparation.
 
All 
 
S
 
.
 
 pyogenes
 
 isolates were
grown overnight in 10 ml of Brain Heart Infusion medium (BHI;
Difco) at 37
 
8
 
C in 15-ml Falcon tubes without agitation. The cells
were pelleted and washed in 1 ml of lysis buffer (10 mM Tris, pH
8, 50 mM EDTA) in a 1.5-ml Eppendorf tube and finally resus-
pended in 400 
 
m
 
l lysis buffer. 4 U of mutanolysin (Sigma-Aldrich),
2 mg of lysozyme, and 40 
 
m
 
g of RNaseA (Sigma-Aldrich) were
added. After incubating the samples for 1 h at 37
 
8
 
C with gentle
agitation, 20 
 
m
 
g of proteinase K (Sigma-Aldrich) was added and
incubated for an additional 30 min. Then, 40 
 
m
 
l of a 20% sarcosyl
solution was added, and the DNA was extracted with phenol/
chloroform and finally precipitated with ethanol. The DNA was
resuspended in 50 
 
m
 
l of TE buffer.
 
Genotyping of S. pyogenes Isolates.
 
Purified genomic DNA
from all 
 
S
 
.
 
 pyogenes
 
 isolates was used for PCR with specific prim-
ers for the 
 
smez
 
, 
 
spe-g
 
, and 
 
spe-h
 
 genes as described previously
(27). In addition, a primer pair specific to a DNA region encod- 
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ing the 23S rRNA, oligo 23rRNA fw (GCTATTTCGGA-
GAGAACCAG) and oligo 23rRNA rev (CTGAAACAT-
CTAAGTAGCTG), was designed and used for PCR as a
positive control.
 
Southern Blot Analysis.
 
About 5 
 
m
 
g of genomic DNA was di-
gested using restriction enzyme HindIII (GIBCO BRL) and
loaded onto a 0.7% agarose gel. The DNA was transferred from
the gel to a Hybond-N
 
1
 
 nylon membrane (Amersham Pharma-
cia Biotech) as described by Maniatis et al. (29). A 640-bp DNA
fragment of the 
 
smez-2
 
 gene was radiolabeled using the
RadPrime Labeling System (GIBCO BRL) and [
 
a
 
-
 
32
 
P]dCTP
(NEN Life Science Products). The nylon blots were hybridized
with the radiolabeled probe in 2
 
3
 
 SSC, 0.5% SDS, 5
 
3
 
 Den-
hardt’s overnight at 65
 
8
 
C. After washing twice in 0.2
 
3
 
 SSC,
0.1% SDS at 65
 
8
 
C, the blots were analyzed on a Storm Phosphor-
Imager
 
®
 
 (Molecular Dynamics).
 
Cloning and Sequencing of smez Alleles.
 
All PCR products ob-
tained from genotyping with different 
 
S
 
.
 
 pyogenes
 
 isolates were
enriched using the Wizard PCR DNA purification system
(Promega) and cloned into T-tailed pBlueScript SKII vectors
(Stratagene) followed by transformation into
 
 Escherichia coli
 
 XL1
blue.
The 
 
smez
 
 genes were analyzed by the dideoxy chain termina-
tion method using a Licor automated DNA sequencer (model
4200). Three subclones of every cloning experiment were ana-
lyzed to insure that no Taq polymerase–related mutations were
introduced. The DNA sequences of the 
 
smez alleles have been
annotated in EMBL/GenBank/DDBJ. The accession numbers
are listed in Table II.
Expression and Purification of Recombinant SMEZ Proteins. Re-
combinant toxins were produced as described previously (27). In
brief, individual smez genes were cloned from pBlueScript vector
into the BamHI-EcoRI cloning site of pGEX-2T expression vec-
tor and transformed into E. coli DH5 cells. For expression of glu-
tathione S-transferase (GST) fusion proteins, the DH5 cells were
grown in tryptone phosphate medium at 308C and induced with
0.1 mM isopropyl-b-d-thiogalactopyranoside (IPTG) at OD600
of 0.7–0.9. The GST fusion proteins were purified on glu-
tathione (GSH) agarose. The mature proteins were then cleaved
off from GST by trypsin digestion and further purified by two
rounds of cation exchange chromatography. Due to their low
isoelectric point, some SMEZ alleles could not be separated from
GST by this method. In these cases, trypsin cleavage was per-
formed on the GSH agarose and the mature toxins were eluted
from the column.
Toxin Proliferation Assay. Human PBLs were purified from
blood of a healthy donor by Histopaque Ficoll (Sigma-Aldrich)
fractionation. The PBLs were incubated in 96-well round-bot-
tomed microtiter plates at 105 cells per well with RPMI-10
(RPMI with 10% FCS) containing varying dilutions of recombi-
nant toxins. The dilution series was performed in 1:5 steps from a
starting concentration of 10 ng/ml of toxin. After 3 d, 0.1 mCi
[3H]thymidine was added to each well and cells were incubated
for an additional 24 h. Cells were harvested and counted on a
scintillation counter.
Jurkat Cell Assay. Jurkat cells (a human T cell line) and LG-2
cells (a human B lymphoblastoid cell line, homozygous for HLA-
DR1) were harvested in log phase and resuspended in RPMI-10.
100 ml of the cell suspension, containing 1 3 105 Jurkat cells and
2 3 104 LG-2 cells, was mixed with 100 ml of varying dilutions
of recombinant toxins on 96-well plates. After incubating over-
night at 378C, 100 ml aliquots were transferred onto a fresh plate
and 100 ml (1 3 104) of SeI cells (IL-2–dependent murine T cell
line) per well was added. After incubating for 24 h, 0.1 mCi
[3H]thymidine was added to each well and cells were incubated
for an additional 24 h. Cells were harvested and counted on a
scintillation counter. As a control, a dilution series of IL-2 was in-
cubated with SeI cells.
For detection of native Vb8-specific exotoxin expression in S.
pyogenes, each isolate was grown in 10 ml of BHI medium over-
night at 378C. Cells were then removed by centrifugation and su-
pernatants were diluted 1:10, 1:50, 1:250, and 1:1,000 in RPMI-
10, and the assay was continued as described above.
Neutralization Assay. PBLs were obtained and stimulated as
described under Toxin Proliferation Assay above, with the ex-
ception that the 10% FCS was replaced by 10% human serum
from various healthy donors. All stimulations were done using 40
pg/ml of recombinant toxin. PBLs from a single donor were used
for all tests. The neutralizing response was determined by com-
paring the T cell proliferation with a control test using 10% FCS
instead of 10% human serum. The mitogenic response obtained
in the absence of human serum was set to 100%.
Results
Genotyping of S. pyogenes Isolates. PCR-based genotyp-
ing was performed in order to determine the frequency of
the recently identified sag genes smez, spe-g, and spe-h in
streptococcal isolates (Table I). The PCR primers for smez
were designed to anneal with both genes, smez and smez-2.
The 103 isolates were collected in New Zealand between
1976 and 1998 from varying sites in patients with varying
infections, although the majority were from sore throats.
They comprised 94 GAS and 9 non-GAS, which were S.
agalactiae (group B), S. equis (group C), and Streptococcus
spp. (group G). There are 22 distinct M/emm types repre-
sented among the GAS isolates, 13 isolates are MNT, and
in 2 cases the M type is unknown. The analysis was under-
taken blinded to the details of each isolate, and two dupli-
cate isolates were included (95/31 and 4202) to demon-
strate the reproducibility of the testing procedure. The
isolates are listed in two groups. Group 1 contained isolates
collected within a large time frame (1976–1996) from all
over New Zealand. Group 2 comprised isolates collected
within a short time (1998) in a distinct area (South Auck-
land schools).
All of the nine non-GAS isolates (belonging to groups B,
C, and G) were negative for the tested sag genes. The fre-
quencies for smez, spe-g, and spe-h within the GAS isolates
were 95.6, 100, and 23.9%, respectively. A correlation be-
tween a certain M/emm type and the presence of the spe-h
gene could not be established. The deficiency in this cur-
rent set was that only five M/emm types were represented
by more than one isolate. The most frequent serotype was
M/emm12 with 13 isolates, from which 7 were positive
and 6 were negative for spe-h, suggesting genetic diversity
within the M/emm12 strain. In contrast, all 12 tested
NZ1437/M89 isolates were negative for spe-h.
The high frequencies of smez and spe-g are of particular
interest, as this has not been described for any other strep-
tococcal sag gene thus far. Other spe genes, like speA, speC,
and ssa, are found at much lower frequencies, and horizon-1768 Antigenic Variation in SMEZ
Table I. Genotyping of Streptococcal Isolates
Group 1: Isolates collected from various parts of New Zealand
between 1976 and 1996 Group 2: Isolates collected from South Auckland schools in 1998
Strain
no. Group
M/
emm Site Disease
Rib.
DNA spe-g spe-h smez Vb8 smez gene
Strain
no.
Student
ID Group
M/
emm Site Disease
Rib.
DNA spe-g spe-h smez Vb8 smez gene
FP 1943 A M53 ts ST 11212 n.d. 4202* 3310 A NZ5118‡ ts ST 11211smez-14
FP 2658 A M59 ts ST 11212smez-12 4202(2)* 3310 A NZ5118‡ ts ST 11211smez-14
FP 4223 A M80 ts ST 11211 n.d. 9606 2252 A MNT ts ST 11212smez-6
FP 5417 A M41 ts ST 11211smez-15 9639 2184 A MNT ts ST 11111smez-3
FP 5847 A M1 ts ST 11211 n.d. 9779 3230 A emm56 ts ST 11211smez-11
FP 5971 A M57 ts ST 11112 n.d. 9893 6144 A PT180 ts ST 11111smez-4
1/5045 A M4 ts ST 11211smez-8 9894 6564 A emm59 ts ST 11211 n.d.
79/1575 A M1 ts Tcarriage 11111smez-1 10019 6264 A emm44 ts ST 11112smez-19
81/3033 A M12 ts ST 11111 n.d. 10028 9366 A emm41 ts ST 11211 n.d.
82/20 A M4 sk Ulcer 11211 n.d. 10134 1880 A ST4547 ts ST 11212smez-5
82/532 A M12 ts ST 11111 n.d. 10303 3564 A emm59 ts ST 11212smez-12
82/675 A NZ1437§ ws Wound 11211 n.d. 10307 4850 A NZ5118‡ ts ST 11211 n.d.
84/141 A M12 ts ST 11111 n.d. 10438 4904 A ST3018 ts ST 11211smez-24
84/1733 A M4 ts ST 11211 n.d. 10463 TSP A emm49 ts ST 11212smez-22
84/781 A NZ1437§ ts ST 11211 n.d. 10649 11510 A ST2267 ts ST 11211smez-16
85/1 A M12 ts ST 11211 n.d. 10730 11503 A MNT ts ST 11212 n.d.
85/167 A M12 ts ST 11111 n.d. 10742 3374 A ST809 ts ST 11211 n.d.
85/314 A NZ1437§ ws Wound 11211 n.d. 10761 3254 A MNT ts ST 11212smez-6
85/437 A M81 ws Inf. eczema 11211smez-8 10763 6614 A PT3875 ts ST 11212smez-18
85/722 A n.d. ? ? 11212smez-23 10782 4850 A MNT ts ST 11111 n.d.
86/435 A M4 ts RF 11211smez-8 10791 10290 A MNT ts ST 11111 n.d.
87/169 A M12 ts ST 11111smez-3 10792 10308 A MNT ts ST 11112smez-6
87/19 A M12 ts ST 11111smez-3 10846 8854 A NZ1437§ ts ST 11211 n.d.
87/781 A M12 ts ST 11211 n.d. 10902 6264 A NZ5118‡ ts ST 11211 n.d.
88/627 A M12 sk Wound 11212 n.d. 10989 5194 A PT2841 ts ST 11212smez-20
89/22 A M12 ts Fever 11211 n.d. 11070 1434 A emm65 ts ST 11122 n.d.
89/25 A M12 ur Erysipelas 11111 n.d. 11072 1880 A ST4547 ts ST 11212smez-5
89/26 A M1 ts AGN 11211 n.d. 11083 4358 A MNT ts ST 11212 n.d.
89/54 A NZ1437§ ts ST 11211 n.d. 11093 9791 A MNT ts ST 11111 n.d.
90/306 A M5 ear Otorrhea 11211smez-4 11152 2030 A PT2612 ts ST 11122 n.d.
90/424 A M4 ts ST 11211 n.d. 11222 4928 A NZ5118‡ ts ST 11111 n.d.
91/542 A M12 ts ST 11211 n.d. 11227 8854 A emm14 ts ST 11212smez-21
94/11 A NZ1437§ ps Abscess 11111 n.d. 11244 2252 A ST4547 ts ST 11212smez-5
94/229 A M49 hvs Endometr. 11122 n.d. 11276 4524 A MNT ts ST 11222 n.d.
94/330 A M4 ts SF 11211 n.d. 11299 2950 A emm80 ts ST 11211smez-9
94/354 A M12 ts ST 11211 n.d. 11574 3186 A ST809 ts ST 11211smez-7
94/384 A M4 sk Wound 11211 n.d. 11580 3280 A emm53 ts ST 11212smez-10
94/712 A NZ1437§ ws Cellulitis 11211 n.d. 11610 2424 A emm57 ts ST 11122 n.d.
95/127 A NZ1437§ bc Cellulitis 11211 n.d. 11646 1880 A ST4547 ts ST 11212 n.d.
95/31i A NZ1437§ ws Abscess 11211smez-13 11681 3564 A emm12 ts ST 11211smez-3
95/31(2)i A NZ1437§ ws Abscess 11211 n.d. 11686 5528 A PT5757 ts ST 11211smez-17
95/361 A NZ1437§ ps Abscess 11211 n.d. 11745 12397 A emm59 ts ST 11212 n.d.
96/1 A n.d. ? ? 11211 n.d. 11789 1568 A MNT ts ST 11212smez-6
96/364 A NZ1437§ bc Burns 11211 n.d. 11802 3266 A MNT ts ST 11212 n.d.
96/551 A M4 eye Eye infect. 11211 n.d. 11869 2950 A ST4547 ts ST 11212smez-5
96/610 A M4 ts SF 11211 n.d. 11961 4916 A MNT ts ST 11212 n.d.
D21 A M1 ts Tcarriage 11211 n.d. 12015 12373 A emm59 ts ST 11112 n.d.
RC4063 C – ts ST 12222 2 7625 8215 B – ts ST 12222 2
SP9205 C – ts ST 12222 2 8011 3238 B – ts ST 12222 2
NI6174 G – ts ST 12222 2 10388 1653 G – ts ST 12222 2
NI6192 B – ts ST 12222 2 OI2633 5395 B – ts ST 12222 2
VC4141 G – ts ST 12222 2
The isolates were collected in New Zealand between 1976 and 1996 (group 1) and from South Auckland schools in 1998 (group 2) from patients
with varying diseases. The results are based on PCR analysis using purified genomic DNA and specific primers for each of the sag genes. The non-
GAS are: B, S. agalactiae; C, S. equis; G, Streptococcus spp. Site and disease abbreviations are as follows: ts, throat site; ws, wound site; sk, skin; ps, pus
site; hvs, high vaginal site; bc, blood culture; ST, sore throat; RF, rheumatic fever; AGN, acute glomerulonephritis; T carriage, throat carriage. n.d.,
not determined.
*Duplicate isolates.
‡Recently assigned as M92.
§Recently assigned as M89.
iDuplicate isolates.1769 Proft et al.
tal gene transfer might explain the varying frequencies of
these genes in different strains. In contrast, both smez and
spe-g were found in virtually all tested GAS isolates. Only
four GAS isolates (11152, 11070, 94/229, and 11610)
tested negative for smez. These were PT2612, emm65,
M49, and emm57. Southern hybridization was performed
to find out if the negative PCR results were due to lack of
the smez gene or to lack/alteration of the primer binding
site(s). HindIII-digested genomic DNA of selected strepto-
coccal isolates was probed with a 640-bp radiolabeled smez-2
PCR fragment (Fig. 1). The smez gene is located on a
1953-bp HindIII DNA fragment in the M1 strain (700294;
American Type Culture Collection) corresponding to frag-
ment A in the Southern blot. In all four PCR-negative iso-
lates, the smez probe hybridized to a HindIII fragment of
z4 kb (fragment B), but not to the smez bearing fragment
A (samples 17, 26, 57, and 67). In addition, the smez probe
bound to a second DNA fragment of z4.2 kb (fragment
C) in isolate 11152 (sample 17). In the M1 reference strain
(lane 1) and in isolate 4202 (sample 50), the smez probe
also bound to fragment B, in addition to fragment A. Frag-
ment B in the M1 strain contains a 180-bp region that
shares 97% sequence homology with the 39 end of the smez
gene. These results suggest that the four PCR-negative iso-
lates possess a truncated smez gene or a smez-like sequence,
but not a complete smez gene.
Identification of Multiple smez Alleles. DNA sequence
analysis of the smez genes from different S. pyogenes isolates
was performed. 37 isolates were analyzed, representing 22
M/emm types, 5 MNT isolates, and 2 isolates of unknown
M type (Table II). 23 different alleles were identified,
bringing the total number of smez alleles to 24 (smez is
hereafter referred to as smez-1). The smez gene appears to
be in linkage equilibrium with the M/emm type. Only
three smez alleles (smez-3, smez-4, and smez-8) were found
in more than one M/emm type. smez-3 was found in all
three tested M/emm12 type isolates plus one MNT. smez-4
was found in one M5 and in one PT180. smez-8 was found
Figure 1. Southern blot analysis of genomic DNA with radiolabeled
smez. HindIII-digested genomic DNA from various Streptococcus isolates
was hybridized with a radiolabeled smez probe. Band A is a 1953-bp
HindIII DNA fragment that carries the smez gene. Bands B and C are
DNA fragments of z4 and 4.2 kbp, respectively, which both carry a
smez-like region. M1, S. pyogenes reference strain (M1 type, 700294;
American Type Culture Collection); 2, isolate 9639 (MNT); 9, isolate
11789 (MNT); 7, isolate 11152 (PT2612 type); 21, isolate RC4063
(group C Streptococcus); 26, isolate 11070 (emm65 type); M, DNA
marker lane; 50, isolate 4202 (NZ5118/M92 type); 57, isolate 94/229
(M49 type); 67, isolate 11610 (emm57 type); 92, isolate 95/127
(NZ1437/M89 type); and 100, isolate 94/330 (M4 type).
Table II. List of All smez Variants Identified To Date
Gene Protein pI P50 M/emm type
Accession
no.
pg/ml
smez-1 SMEZ-1 5.4 0.1 M1 –‡
smez-2 SMEZ-2 6.98 0.02* n.d. AF086626
smez-3 SMEZ-3 6.98 0.25
MNT,
emm12, M12 AF143653
smez-4 SMEZ-4 5.73 n.d. PT180, M5 AF143654
smez-5 SMEZ-5 5.17 0.7 ST4547 AF143655
smez-6 n.f. – – MNT AF143656
smez-7 SMEZ-7 6.14 0.3 ST809 AF143657
smez-8 SMEZ-8 5.17 0.25 M4, M81 AF143658
smez-9 SMEZ-9 8.86 0.2 emm80, M80 AF143659
smez-10 SMEZ-10 5.4 n.d. emm53, M53 AF143660
smez-11 SMEZ-11 8.86 n.d. emm56 AF143661
smez-12 SMEZ-12 5.17 n.d. emm59, M59 AF143662
smez-13 SMEZ-13 6.14 0.2 NZ1437 AF143663
smez-14 SMEZ-14 6.14 n.d. NZ5118 AF143664
smez-15 SMEZ-15 5.02 n.d. M41 AF143665
smez-16 SMEZ-16 7.82 n.d. ST2267 AF143666
smez-17 SMEZ-17 8.86 n.d. PT5757 AF143667
smez-18 SMEZ-18 9.62 n.d. PT3875 AF143668
smez-19 n.f. – – emm44 AF143669
smez-20 SMEZ-20 7.82 0.09 PT2841 AF143670
smez-21 SMEZ-21 6.14 0.3 emm14 AF143671
smez-22 SMEZ-22 6.98 0.3 emm49 AF143672
smez-23 SMEZ-23 – – n.d. AF143673
smez-24 SMEZ-24 8.85 n.d. ST3018 AF143674
smez-6, smez-19, and smez-23 all have a single base pair deletion causing
a frame shift. With the exception of smez-3, smez-4, and smez-8, all
analyzed variants could be correlated to a single M/emm type. pI,
calculated isoelectric point; P50, half-maximal mitogenic potency; n.d.,
not determined; n.f., nonfunctional (pseudogene).
*Described previously (reference 28).
‡Published previously (reference 27).1770 Antigenic Variation in SMEZ
in one M4 and in one M81 type strain. Four of the five
MNT isolates carry smez-6 and one carries smez-3.
With the exception of smez-6, smez-19, and smez-23,
which have individual single base pair deletions causing
frame shifts, all smez alleles possess complete open reading
frames. smez-2, which was isolated from a separate strain,
was not found in any of the current panel of isolates. The
21 intact smez genes encode 21 different SMEZ variants.
Sequence identities between smez alleles are between
94.5 (smez-1 and smez-2) and 99.9% (equivalent to one
base pair difference), e.g., smez-4 and smez-7. A family tree
of the 24 smez alleles was established based on DNA se-
quence homology (Fig. 2). The smez alleles were grouped
into two clusters. Group A comprises smez-1, smez-5, smez-
8, smez-10, smez-12, and smez-15. All other smez alleles are
in group B. Sequence variation between all smez alleles is
restricted to only 62 nucleotide positions, or 9.8% of the
coding region for the mature protein (Table II). Most of
the variations are G/A and T/C transitions, while transver-
sions only occur at position 290 (A/C), 291 (A/T), and
358 (G/C). 31 of the variable positions (50%) result in
amino acid changes; the other 50% are silent exchanges.
The frequency of a nucleotide exchange at a particular po-
sition also varies significantly within the 24 smez alleles. 17
of the 62 sites are point mutations for single alleles, while
the remaining 45 sites are point mutations common to 2 or
more alleles. The most variable sites are positions 231, 234,
and 238 and occur in 12 alleles (50%). Some of these highly
variable nucleotides are linked together and build five dis-
tinct regions (Table III). One region (III) comprising 10
polymorphic sites between nucleotide 282 and 298 occurs
in only 2 combinations within the 24 smez alleles. These
combinations segregate the two main groups of the smez
family tree. The other four blocks are less conserved, and
sequence combinations between these blocks occur in sev-
eral alleles, generating gene mosaics. Interestingly, the
polymorphic sequence blocks are more frequent in the
center of the gene, between nucleotide positions 231 and
427. Only one polymorphic block (V) is in the last third of
the gene. No blocks occur in the first third. The sequence
clusters and mosaic distribution are also reflected in the
amino acid sequence (Table IV). Interestingly, the five
polymorphic amino acid positions within block III are all
between amino acid positions 91 and 100 and are therefore
clustered closer together than in the other blocks. The
amino acid composition of this polymorphic block influ-
ences the isoelectric point of the SMEZ variants. All group
A variants have a pI between 5.02 and 5.4, whereas the pIs
of group B SMEZ are between 5.73 and 9.62 (Table II).
Expression of SMEZ Variants by S. pyogenes Isolates.
Both SMEZ-1 and SMEZ-2 specifically target human
Vb8-bearing T cells (27). Jurkat cells (a Vb8 T cell line)
were used to determine SMEZ expression from S. pyogenes
culture supernatants from all 103 streptococcal isolates (see
Materials and Methods). 62 isolates (66% of the GAS iso-
lates) showed Vb8-stimulating activity. No Vb8 activity
was detected from the nine non-GAS, the four smez PCR-
negative GAS strains, and the isolates carrying the pseudo-
genes smez-6, smez-19, or smez-23. These results suggest
that SMEZ is the only Vb8-targeting SAg in S. pyogenes.
Culture supernatant from 12 isolates with complete open
reading frames for smez did not stimulate Jurkat cells. These
isolates possess smez-5, smez-10, smez-12, smez-18, smez-
20, smez-21, or smez-22. These results suggest the follow-
ing possibilities: (a) those isolates do not express SMEZ un-
der the selected growth conditions; (b) mutations outside
the smez coding region repress gene expression; or (c) these
isolates express SMEZ variants that have lost their specific-
ity to target Vb8 T cells. Recombinant SMEZ variants
were generated in E. coli using the GST expression system.
Successful recombinant expression was achieved for
rSMEZ-3, rSMEZ-5, rSMEZ-7, rSMEZ-8, rSMEZ-9,
rSMEZ-13, rSMEZ-20, rSMEZ-21, and rSMEZ-22. Fusion
proteins were completely soluble and gave yields of z30
mg/liter. The purified recombinant toxins were applied to
isoelectric focusing (Fig. 3). Isoelectric points between
SMEZ variants were consistent with the calculated pIs (Ta-
ble II).
Native conformation of the recombinant toxins was
confirmed by human T cell proliferation assay. All purified
SMEZ variants were active on human T cells with similar
Figure 2. smez gene family tree. The family tree was created using the
PileUp program v8 (Genetic Computer Group) and is based on nucle-
otide sequence homology. The smez family can be divided into two ma-
jor groups based on a conserved DNA region (region III). smez-6, smez-
19, and smez-23 are pseudogenes with a single base pair deletion causing
a frame shift.1771 Proft et al.
Table III. DNA Sequence Alignment of smez Alleles
Only the 62 variable nucleotides (9.8% of the smez gene) are shown, of which 17 are point mutations for single alleles and 45 are common to 2 or
more alleles. Some of the variable sites are linked together, building sequence blocks (shaded gray) within five distinct regions (I–IV). In region III,
only two sequence combinations occur, correlating with the two major branches (groups A and B) of the smez family tree (see Fig. 2). Combinations
between sequence blocks within the other four regions in different alleles generate gene mosaics.1772 Antigenic Variation in SMEZ
half-maximal responses (P50 values) between 0.09 and 0.3
pg/ml, except for rSMEZ-5 with a P50 of 0.7 pg/ml, and
rSMEZ-10 and rSMEZ-12, which gave P50 values of 2 and
15 pg/ml, respectively (Table II).
rSMEZ-5, rSMEZ-20, rSMEZ-21, and rSMEZ-22 all
stimulated Jurkat cells (Fig. 4), thus confirming that the
lack of Vb8-stimulating activity of wild-type streptococcal
culture supernatants is due to lack of expression rather than
altered Vb specificity of the SMEZ variants produced.
Antigenic Variation in SMEZ Variants. Human sera from
100 healthy donors were tested for the presence of natu-
rally acquired neutralizing antibodies to SMEZ variants
rSMEZ-1, rSMEZ-2, rSMEZ-3, rSMEZ-5, rSMEZ-7,
rSMEZ-8, rSMEZ-9, rSMEZ-13, rSMEZ-20, rSMEZ-21,
and rSMEZ-22. The neutralizing response was determined
as the percentage of inhibition of T cell stimulation by
SMEZ in the presence of 10% human serum versus 10%
FCS. More than 75% inhibition was defined as full, 30–
75% as moderate, and ,30% as negative neutralization.
Figure 3. Isoelectric focusing
gel. 2 mg of purified recombi-
nant toxin was run on a 5.5%
polyacrylamide isoelectric focus-
ing gel (pH 5–8). The gel shows
significant variation of the iso-
electric point between SMEZ
variants. Toxins with low iso-
electric points, such as rSMEZ-5
and rSMEZ-8, belong to group
A of the SMEZ family. Members
of group B are characterized by a
more basic isoelectric point.
Figure 4. Jurkat cell assay. Jurkat cells (bearing a Vb8 TCR) and LG-2
cells were mixed with varying concentrations of recombinant toxin and in-
cubated for 24 h, before SeI cells were added. After 1 d, 0.1 mCi [3H]thy-
midine was added and cells were counted after an additional 24 h. s, un-
stimulated; , , rSMEZ-1; m, rSMEZ-5; j, rSMEZ-20; e, rSMEZ-21;
and d, rSMEZ-22.
Table IV. Amino Acid Alignment of SMEZ Alleles
Only the 31 variable residues are shown (14.9% of the mature SMEZ protein). The sequence blocks and mosaic structure seen in the DNA sequence
alignment (Table III) are also reflected in the amino acid sequence.1773 Proft et al.
85 sera fully neutralized the activity of all 11variants tested.
The remaining 15 sera displayed only partial neutralizing ac-
tivity on a subset of the variants. 20 sera were selected for a
repeat test, and the confirmed results are shown in Table V.
Seven sera (26, 32, 39, 73, 86, 99, and 100) displayed very
different neutralizing response profiles, suggesting the exist-
ence of variant (epitope) specific antibodies. For example, se-
rum 86 strongly neutralized rSMEZ-1 and rSMEZ-5, but
none of the other variants. Interestingly, both SMEZ-1 and
SMEZ-5 belong to group A and share a common amino
acid stretch in region III (Table IV). However, serum 86 did
not effectively neutralize another group A variant, rSMEZ-8.
The only amino acid differences between SMEZ-1, SMEZ-5,
and SMEZ-8 that could explain this different neutralization
are residues D62A, M68V (both in region I), and P117T (in
region VI). Thus, for serum 86, the likely neutralizing
epitopes must include one of these three residues.
Serum 39 was similar to serum 86, and sera 73 and 75
also neutralized rSMEZ-8–stimulated T cells. SMEZ-1 and
SMEZ-5 were commonly neutralized by most of the sera
tested. Only two sera (30 and 31) displayed less than com-
plete neutralization responses. In contrast, SMEZ-2 activity
was not inhibited by eight sera, and another six sera
showed only moderate inhibition. SMEZ-2 was therefore
the least commonly neutralized variant.
Discussion
SMEZ is the most potent bacterial SAg so far discovered,
with specificity towards Vb4- and Vb8-bearing human T
cells. Unlike all other SAgs, SMEZ is highly polymorphic,
having arisen from genetic mosaicism at a single genetic lo-
cus. 22 different smez alleles were found in 21 different
M-type positive GAS isolates obtained over a 15-yr period
throughout New Zealand, in addition to the 2 alleles, smez
and smez-2, described previously (27, 28). All of the 94 iso-
lates tested positive for the smez gene by PCR or Southern
analysis. Thus, smez is not only the most potent SAg, it is
also the most prevalent. The polymorphism in the SMEZ
protein results in antigenic variants that are not consistently
neutralized by naturally occurring antibodies present in
normal adult human sera, yet the human TCR b chain
profile remains steadfastly Vb4 and Vb8.
Genetic Mosaicism. The variation in smez has most likely
arisen through gene mosaicism, and the strongest indicator
for this is that 30 out of 31 polymorphic positions have
only 2 possible amino acids. The mechanism for gene mo-
saics is homologous recombination between two copies of
a gene, and Southern blot analysis shows that some isolates
indeed carry a second smez gene or smez-like sequence.
However, homologous recombination of smez-1 with the
smez-like sequence on the M1 genome would result in an-
other pseudogene due to a nonsense mutation within the
smez-like sequence. Moreover, .2 homologous genes
would be needed to generate the mosaic pattern seen in the
24 smez alleles. The different sequence segments appear to
have originated from different strains, suggesting the pos-
sibility of intergenic recombination with a horizontally
transferred homologous gene from another strain. Inter-
strain transfer followed by homologous recombination has
Table V. Neutralization Assay
Human sera from 100 healthy New Zealand donors were used to study the presence of antibodies neutralizing the mitogenic activity of recombinant
SMEZ variants. The figures given are the percentage of inhibition compared with a reference test in which human serum was replaced by FCS. The
table shows the results obtained with 20 selected sera. The remaining 80 sera all showed high neutralizing responses for the whole panel of variants.1774 Antigenic Variation in SMEZ
been reported to play a key role in the evolution of emm-
like genes (30), indicating that such a mechanism exists in
S. pyogenes.
Sequence combination between different alleles is not
the only mechanism to create variability in the smez gene.
11 of the 31 variable residues of the SMEZ variants corre-
late with individual point mutations for single alleles and
must have occurred independently in the respective strains.
This is also remarkable, given the fact that such a high mu-
tation rate is not observed in any other sag genes, including
spe-g, which was also found in all isolates tested. It is possi-
ble that point mutations in other sag genes are eliminated
by selective pressure in order to maintain functionality of
the toxin. However, this seems unlikely, since the variant
residues in SMEZ do not contribute to the overall structure
and are not conserved within the SAg family.
Allelic variation has been described for the staphylococ-
cal enterotoxin C (SEC). SEC1 and SEC2 differ by only
seven amino acid residues, but target a different set of TCR
(31). Also, SEA and SEE, which still share 85% amino acid
sequence identity, vary in their TCR specificity (32).
Protein expression of a Vb8-stimulating toxin was ob-
served in the culture supernatant of 66% of the GAS iso-
lates. No Vb8 activity was found in any of the isolates that
carry a defective smez gene, suggesting that smez is the only
Vb8-specific toxin in S. pyogenes. Since the smez gene has
been analyzed in only a fraction of the GAS panel, it is pos-
sible that more nonfunctional smez alleles occur in the nat-
ural  S. pyogenes population. Of the identified complete
smez genes, 7 out of 21 did not express the SMEZ protein,
suggesting a tight control of gene transcription. However,
it is important not to assume that expression under in vitro
conditions always equates to expression in vivo. Interest-
ingly, the SMEZ-producing strains include M1, M4, and
M12 types. These are connected to STLS (33), whereas the
SMEZ-13–producing NZ1437/M89 type strain is con-
nected to rheumatic fever in New Zealand (34). A larger
panel of GAS isolates, in particular those known to cause
invasive diseases, must be analyzed for SMEZ expression to
identify any connection between expression of a certain
SMEZ variant and streptococcal diseases.
Antigenic Variation. There are 31 variable amino acid
positions in SMEZ. Analysis of a recent SMEZ-2 crystal
structure shows that 26 of these residues are surface ex-
posed and scattered across the entire protein. Only five of
the variable positions have side chains that are buried, and
all are conservative changes, indicating that there has been
selective pressure to vary the surface of the molecule while
preserving structural integrity of the molecule (34a). Wide-
spread prevalence of SMEZ-producing strains of S. pyogenes
in the normal adult human population was confirmed by
seroconversion in 100/100 normal healthy young adults.
However, 15% of the sera showed only partial neutraliza-
tion profiles against a panel of recombinant SMEZ variants.
SMEZ-1 was the most commonly neutralized, whereas
SMEZ-2 was the least. SMEZ-2 is a rare variant that has
not yet been found in any S. pyogenes isolate in New
Zealand. SMEZ-2 was identified in a single isolate of un-
known M/emm type from a patient with rheumatic fever
in the United States, and is the most potent variant known
to date (27). In contrast, SMEZ-1 was found associated
with the M1 strain, a very common strain in New Zealand.
These data suggest that certain SMEZ variants are better
capable of generating a generic protective neutralizing re-
sponse against all SMEZ variants than others, and that pro-
tective antibodies offer only partial protection against a
subset of SMEZ variants. This raises an interesting question
of whether individual SMEZ variants are linked to disease
severity. Screening patients with severe streptococcal-medi-
ated disease for lack of seroconversion against individual
SMEZ variants might provide information in this regard.
The strong linkage between the smez gene and the emm
gene, which codes for the major polymorphic surface anti-
gen M protein, offers one explanation for the mechanisms
of smez genetic variation. The smez gene is located 14 kb
upstream from the Vir regulon. The M protein represents
the major neutralizing surface antigen on Streptococci, and
generation of diversity in the M protein antigenic determi-
nants might also affect neighboring genes. Thus far, we
have analyzed only 21 different M/emm types for the smez
gene. It is likely that the actual number of smez alleles
among the S.  pyogenes population is much higher. This
might be of particular interest, as the epidemiology of
streptococcal disease appears to be connected to certain M
types, and temporal shifts in prevalence of certain M types
occur (35).
Role of SMEZ. SAgs interfere with host adaptive im-
mune responses, driving profound Th1-type responses in
an antigen-nonspecific way characterized by high levels of
INF-g, IL-2, and nonspecific T cell proliferation. How
this response improves survival of the bacteria has yet to be
clearly established, but one might argue that the prime
function is to prevent the production of high affinity cyto-
toxic antibodies by promoting a cellular, Th1-mediated
response. The high degree of antigenic variation is good
evidence that SMEZ provides a significant growth advan-
tage for S. pyogenes and that the variation at this locus has
been driven primarily by the need to escape antibody neu-
tralization, rather than through a need to expand its T cell
repertoire.
Retention of the TCR Specificity. In contrast to the anti-
genic diversity, the TCR Vb binding site of SMEZ appears
to be unaffected by surrounding amino acid variation. One
conclusion to draw from this is that Vb4- and Vb8-bearing
T cell subsets are uniquely important in host defence
against  Streptococci. However, one could also argue that re-
tention of this T cell specificity is due to the physical con-
straints of the SMEZ–TCR b chain interaction, so that
other TCR b chains cannot be effectively accommodated
without loss of SAg activity. However, the fact that SMEZ
effectively targets murine TCR b chains (27) suggests that
there are no special constraints on the SMEZ–TCR bind-
ing site. Why SMEZ should be privy to such extensive
variation while all other SAgs are substantially invariant is
unclear, but does point to an important role of this particu-
lar SAg in the survival of all group A Streptococci. There are1775 Proft et al.
examples of allelic variation in other streptococcal SAgs,
such as SPEA (24), SPE-C (36), and SSA (37), but to a
much lesser degree and without the mosaicism seen at the
smez locus. Genes with mosaic structures are known in
other pathogenic organisms such as streptokinase (skn [38]),
the emm-like genes (30), or the Streptococcus pneumoniae au-
tolysin gene (lytA [39]), and each codes for an important
virulence factor.
The antigenic variation appears to have arisen through
the selective advantage that SAg escape mutants provide to
the species S. pyogenes. This is perhaps the best evidence yet
that the SAgs confer an advantage on the strain that pro-
duces it. Moreover, the ubiquitous expression and genetic
variation tend to suggest that smez, more than other SAgs,
significantly enhances the survival of group A Streptococci in
general and thus might be linked to increased virulence and
streptococcal disease severity. The smez locus may provide
an important genotyping locus to examine virulence and
disease susceptibility, and may also offer a potential target
for streptococcal vaccine development.
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